Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-11.60 Insider Own9.43% Shs Outstand2.55M Perf Week1.55%
Market Cap8.34M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.31M Perf Month-6.57%
Income-20.42M PEG- EPS next Q-0.39 Inst Own53.35% Short Float / Ratio1.45% / 2.25 Perf Quarter2.51%
Sales0.08M P/S104.23 EPS this Y88.53% Inst Trans- Short Interest0.03M Perf Half Y-17.34%
Book/sh8.76 P/B0.37 EPS next Y- ROA-90.43% Target Price6.00 Perf Year14.36%
Cash/sh10.15 P/C0.32 EPS next 5Y- ROE-110.63% 52W Range1.86 - 9.01 Perf YTD13.15%
Dividend- P/FCF- EPS past 5Y66.41% ROI-90.69% 52W High-63.71% Beta0.84
Dividend %- Quick Ratio5.83 Sales past 5Y748.79% Gross Margin-218.67% 52W Low75.81% ATR0.29
Employees18 Current Ratio5.83 Sales Q/Q- Oper. Margin-27308.00% RSI (14)48.92 Volatility10.02% 8.98%
OptionableNo Debt/Eq0.02 EPS Q/Q65.39% Profit Margin-27230.67% Rel Volume0.34 Prev Close3.34
ShortableYes LT Debt/Eq0.01 EarningsNov 13 BMO Payout- Avg Volume14.86K Price3.27
Recom1.00 SMA20-2.66% SMA50-2.36% SMA200-7.89% Volume5,048 Change-2.10%
Date Action Analyst Rating Change Price Target Change
Oct-05-20Downgrade Ladenburg Thalmann Buy → Neutral
Apr-20-20Initiated Ladenburg Thalmann Buy $14
Feb-26-16Downgrade Maxim Group Buy → Hold
Dec-31-15Reiterated Maxim Group Buy $23 → $14
Sep-16-15Reiterated Maxim Group Buy $4 → $23
Nov-30-23 07:00AM
Nov-17-23 08:00AM
Nov-13-23 08:00AM
Sep-21-23 08:00AM
Aug-21-23 09:02PM
09:02PM Loading…
Aug-18-23 09:02PM
Aug-11-23 01:00PM
Aug-08-23 10:30PM
Jul-25-23 01:00PM
Jun-26-23 08:00AM
May-15-23 08:00AM
May-08-23 08:05AM
Feb-13-23 08:00AM
Jan-23-23 09:48AM
08:00AM Loading…
Nov-10-22 08:00AM
Sep-16-22 08:42AM
Sep-12-22 10:06PM
Sep-02-22 08:00AM
Jul-15-22 06:52AM
May-16-22 08:15AM
Feb-14-22 08:00AM
Jan-18-22 12:53PM
Jan-17-22 09:30AM
Nov-27-21 06:54AM
Nov-15-21 08:00AM
Sep-20-21 08:00AM
Sep-13-21 03:58PM
Sep-08-21 08:10AM
08:00AM Loading…
May-31-21 01:54AM
Apr-27-21 09:55PM
Mar-23-21 12:18PM
Feb-24-21 09:26AM
Dec-07-20 02:33PM
Dec-02-20 12:06AM
Oct-06-20 04:05PM
Oct-02-20 09:05AM
Sep-23-20 04:54PM
Sep-01-20 08:15AM
Jul-08-20 08:00AM
Apr-20-20 06:49AM
Apr-15-20 08:52AM
Apr-14-20 09:28PM
Mar-30-20 10:09AM
Mar-26-20 09:44AM
Feb-27-20 06:18PM
Jan-31-20 08:08AM
Nov-27-19 08:00AM
Nov-17-19 07:02PM
Nov-15-19 07:00AM
Oct-31-19 08:30AM
Sep-30-19 09:24AM
Sep-19-19 09:15AM
Sep-16-19 08:00AM
Sep-15-19 09:49PM
Jul-31-19 08:30AM
Jul-11-19 11:34PM
Jun-06-19 08:09AM
May-08-19 08:01PM
Mar-06-19 09:52PM
Jan-29-19 09:46PM
Dec-21-18 10:10AM
Nov-23-18 12:01AM
Nov-15-18 07:35AM
Sep-19-18 08:00AM
Jul-14-18 02:02PM
Jul-10-18 05:15PM
Jul-09-18 11:04AM
Jul-08-18 08:59PM
May-31-18 08:00AM
May-15-18 08:00AM
May-03-18 08:00AM
Apr-24-18 08:00AM
Mar-05-18 08:00AM
Feb-22-18 08:30AM
Jan-23-18 04:17PM
Jan-16-18 08:00AM
Nov-27-17 09:30AM
Oct-18-17 07:45AM
Sep-05-17 02:54PM
Sep-01-17 04:00PM
Aug-08-17 08:30AM
Apr-05-17 07:30AM
Apr-04-17 04:40PM
Mar-27-17 09:30AM
Mar-13-17 06:00AM
Feb-16-17 08:00AM
Feb-03-17 09:45AM
Feb-02-17 12:05PM
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firms' proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on November 22, 2019 and is headquartered in Hayward, CA.